Literature DB >> 15073146

Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism.

Alfredo Ulloa-Aguirre1, Jo Ann Janovick, Alfredo Leaños-Miranda, P Michael Conn.   

Abstract

GnRH plays an essential and central role in neuroendocrine control of reproductive function. The GnRH receptor is located on the plasma membrane of gonadotrophs, pituitary cells that synthesize the gonadotrophins LH and FSH. This receptor belongs to the superfamily of G protein-coupled receptors, and is preferentially coupled to the G(q/11) protein; its activation by GnRH analogues stimulates the synthesis and release of LH and FSH. Resistance to GnRH by inactivating (loss-of-function) mutations of the human GnRH receptor leads to distinct forms of sporadic or inherited hypogonadotrophic hypogonadism. Although in vitro expression of a number of these mutated GnRH receptors in heterologous systems has shown that these mutations appear to alter several functions of the molecule, including ligand binding, receptor activation or interaction with coupled effectors, recent observations from our laboratory have challenged this view and indicated that protein misfolding and resultant misrouting is a mechanism that, by itself, may lead to loss of function of the human GnRH receptor. In this review we describe the experimental data that led us to this conclusion and how these studies revealed previously unsuspected features of the mutant human GnRH receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073146     DOI: 10.1093/humupd/dmh015

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  13 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism.

Authors:  Guadalupe Maya-Núñez; Jo Ann Janovick; Arturo Aguilar-Rojas; Eduardo Jardón-Valadez; Alfredo Leaños-Miranda; Teresa Zariñan; Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2011-01-26       Impact factor: 4.102

Review 3.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

Review 4.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

5.  Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor.

Authors:  Rodrigo Ayala Yáñez; P Michael Conn
Journal:  Cell Biochem Funct       Date:  2010-01       Impact factor: 3.685

Review 6.  Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Adv Pharmacol       Date:  2011

Review 7.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

8.  Participation of the endoplasmic reticulum protein chaperone thio-oxidoreductase in gonadotropin-releasing hormone receptor expression at the plasma membrane.

Authors:  W Lucca-Junior; J A Janovick; P M Conn
Journal:  Braz J Med Biol Res       Date:  2009-02       Impact factor: 2.590

9.  A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

Authors:  P Michael Conn; Emery Smith; Timothy Spicer; Peter Chase; Louis Scampavia; Jo Ann Janovick
Journal:  Assay Drug Dev Technol       Date:  2014-05       Impact factor: 1.738

Review 10.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.